Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:APOG News 8 January 2026 - 9 January 2026

Tecnoglass stock rebounds nearly 8% after Apogee outlook cut — what investors watch next

Tecnoglass stock rebounds nearly 8% after Apogee outlook cut — what investors watch next

Tecnoglass shares jumped nearly 8% to $51.75 in late morning New York trading Thursday, recovering from earlier volatility. The rally followed rival Apogee’s lowered 2026 forecast, which cited a $0.30 per-share tariff impact. Investors are watching Tecnoglass’s upcoming dividend and late-February results window. Apogee shares also rebounded, rising 4.3% after a sharp drop Wednesday.
8 January 2026
··

Stock Market Today

LSEG share price heads into Monday after AI jitters hit London Stock Exchange Group stock

LSEG share price heads into Monday after AI jitters hit London Stock Exchange Group stock

8 February 2026
London Stock Exchange Group shares fell 1.1% to 7,502p Friday, closing out a third straight weekly decline and an 8% drop for the week. The selloff followed renewed concerns over AI disruption after a new Claude plug-in from Anthropic and caution over Big Tech’s AI spending. LSEG bought back 256,419 shares on Feb. 5. Investors await Monday’s open and LSEG’s FY25 results webcast on Feb. 26.
Anglo American share price slips after BofA downgrade as De Beers review looms

Anglo American share price slips after BofA downgrade as De Beers review looms

8 February 2026
Anglo American shares closed at 3,435 pence on Friday, down 0.75%, after BofA Global Research downgraded the miner to “neutral” over valuation and execution risks. The bank raised its price target to 3,600 pence but flagged a long wait for Teck synergies and uncertainty around De Beers. Investors await full-year results and updates on deals and disposals on Feb. 20.
GSK stock price: EU nod for Nucala in COPD puts the focus on Monday trade

GSK stock price: EU nod for Nucala in COPD puts the focus on Monday trade

8 February 2026
GSK shares closed Friday up 0.8% at 2,198 pence after the EU approved expanded use of Nucala for adults with uncontrolled COPD. Chairman Jonathan Symonds bought 2,500 shares earlier in the week. The stock is up 17% over the past week and nearly 49% in 12 months. GSK trades ex-dividend on Feb. 19.
Go toTop